SIM0616 / Simcere - LARVOL DELTA

SCR-M030, an innovative and potential first-in-class trispecific T cell engager targeting PSMA and STEAP1 for mCRPC (AACR 2026) - "Notably, in the 22RV1 model, SCR-M030 exhibited more potent tumor suppression than the AMG509 analog. In conclusion, the novel trispecific TCE SCR-M030 is a strategically designed therapy that demonstrates potent efficacy against challenging low-expression tumors by simultaneously targeting PSMA and STEAP1 with differential affinity. Its robust in vivo performance, favorable pharmacokinetics, and superiority over a relevant comparator underscore its strong potential as a next-generation therapeutic for prostate cancer."

Trispecific • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • STEAP1